Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
92 hedge funds and large institutions have $577M invested in Repros Therapeutics Inc. in 2013 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 35 increasing their positions, 28 reducing their positions, and 10 closing their positions.
110% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 10
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
42% more call options, than puts
Call options by funds: $81M | Put options by funds: $57.2M
39% more capital invested
Capital invested by funds: $414M → $577M (+$163M)
25% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 28
14% more funds holding
Funds holding: 81 → 92 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$27.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.95M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$8.51M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$5.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$22.4M |
| 2 |
QF
QVT Financial
New York
|
-$20.1M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$12.1M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$6.54M |
| 5 |
KCM
Kingdon Capital Management
New York
|
-$6.43M |
RPRX Hedge Fund Activity: Q3 2013 in Review
92 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q3 2013, worth a combined $577M — up 39% from $414M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RPRX positions and 10 closed out — a net gain of 11 holders — while 35 added to existing stakes and 28 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $27.9M. The largest seller was Jennison Associates, cutting an estimated $22.4M.
- 92 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q3 2013, up from 81 in Q2 2013.
- Funds reported $577M of Repros Therapeutics Inc. stock for Q3 2013, up 39% quarter-over-quarter.
- 21 funds opened new Repros Therapeutics Inc. positions in Q3 2013 and 10 closed out, a net change of +11 holders.
- The largest Repros Therapeutics Inc. buyer in Q3 2013 was Perceptive Advisors, an estimated $27.9M added.
- The largest Repros Therapeutics Inc. seller in Q3 2013 was Jennison Associates, an estimated $22.4M sold.
Based on aggregated 13F filings for Q3 2013.